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Summary
Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons that results in 
progressive weakness and death from respiratory failure, commonly within about 3 years. Previous studies have 
shown association of a locus on chromosome 9p with ALS and linkage with ALS–frontotemporal dementia. We 
aimed to test whether this genomic region is also associated with ALS in an independent set of UK samples, and to 
identify risk factors associated with ALS in a further genome-wide association study that combined data from the 
independent analysis with those from other countries.
Methods We collected samples from patients with sporadic ALS from 20 UK hospitals and obtained UK control 
samples from the control groups of the Depression Case Control study, the Bipolar Aﬀ ective Case Control Study, and 
the British 1958 birth cohort DNA collection. Genotyping of DNA in this independent analysis was done with Illumina 
HumanHap550 BeadChips. We then undertook a joint genome-wide analysis that combined data from the 
independent set with published data from the UK, USA, Netherlands, Ireland, Italy, France, Sweden, and Belgium. 
The threshold for signiﬁ cance was p=0·05 in the independent analysis, because we were interested in replicating a 
small number of previously reported associations, whereas the Bonferroni-corrected threshold for signiﬁ cance in the 
joint analysis was p=2·20×10–⁷.
Findings After quality control, samples were available from 599 patients and 4144 control individuals in the 
independent set. In this analysis, two single nucleotide polymorphisms in a locus on chromosome 9p21.2 were 
associated with ALS: rs3849942 (p=2∙22×10–⁶; odds ratio [OR] 1∙39, 95% CI 1·21–1·59) and rs2814707 (p=3∙32×10–⁶; 
1∙38, 1·20–1·58). In the joint analysis, which included samples from 4312 patients with ALS and 8425 control 
individuals, rs3849942 (p=4∙64×10–¹⁰; OR 1∙22, 95% CI 1·15–1·30) and rs2814707 (p=4∙72×10–¹⁰; 1∙22, 1·15–1·30) 
were associated with ALS. 
Interpretation We have found strong evidence of a genetic association of two single nucleotide polymorphisms on 
chromosome 9 with sporadic ALS, in line with ﬁ ndings from previous independent GWAS of ALS and linkage studies 
of ALS–frontotemporal dementia. Our ﬁ ndings together with these earlier ﬁ ndings suggest that genetic variation at 
this locus on chromosome 9 causes sporadic ALS and familial ALS–frontotemporal dementia. Resequencing studies 
and then functional analysis should be done to identify the defective gene.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a 
neurodegenerative disease of motor neurons that 
results in progressive weakness and death from 
respiratory failure, commonly within about 3 years. 
About one in 300 people1 develops ALS but its prevalence 
is low—ﬁ ve per 100 000 people—because of its poor 
prognosis. About 5% of patients have a family history of 
ALS, and occasionally frontotemporal dementia. ALS 
and frontotemporal dementia can coexist in the same 
family or individual.
Several studies have reported linkage of ALS–
frontotemporal dementia with a locus on chromosome 9p, 
and speciﬁ cally with a shared region that spans about 
3∙6 Mb.2–7 A genome-wide association study (GWAS) 
reported that sporadic ALS was associated with single 
nucleotide polymorphisms (SNPs) in the same region 
of chromosome 9p.8 Therefore, this locus is the focus of 
research into the genetic basis of familial ALS, the 
relation between ALS and frontotemporal dementia, 
and the mechanisms underlying sporadic ALS and 
frontotemporal dementia. 
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Previous GWAS in ALS have reported association results 
that have been replicated within the same study but rarely 
in independent studies.9 For example, variation in the 
ITPR2 gene was associated with ALS in a GWAS and was 
replicated within the study10 but has not been found by 
other investigators.8 Variation in DPP6 was reported to be 
associated with ALS and was replicated within the same 
study,11 and a second study found that the same SNPs were 
the most strongly associated, although they did not achieve 
genome-wide signiﬁ cance.12 A subsequent study failed to 
conﬁ rm the ﬁ ndings.13 Variation in the UNC13A gene was 
strongly associated with ALS and was replicated within 
the same study,8 but no successful replication of the 
association with this locus has been reported.
We therefore aimed to examine previously reported 
genetic associations for ALS in a GWAS in an independent 
set of UK samples. We also aimed to combine these data 
with existing genotypic data from seven other countries 
to generate a large GWAS in ALS. 
Methods
Samples 
Adults attending one of 20 UK hospitals and who had 
been diagnosed with ALS by two consultant neurologists 
were invited to participate in the UK National DNA Bank 
for Motor Neuron Disease Research (MND DNA bank), a 
national collection of ALS DNA samples derived from 
whole blood. Collection began in 2004, and enrolment is 
ongoing. Patients had no family history of ALS at the time 
of sampling, were of self-reported white European 
ancestry, and had onset of weakness on or after January, 
2002. Patients provided ethically approved written consent 
for blood to be drawn. Control samples for the independent 
analysis were obtained from two sources: the control 
groups of the Depression Case Control (DeCC) study14 
and the Bipolar Aﬀ ective Case Control Study (BACCS)15 
and data deposited by Panos Deloukas from the Wellcome 
Trust Sanger Institute (Cambridge, UK) and published 
online from the British 1958 birth cohort DNA collection. 
Case and control samples for the joint analysis were 
from the UK, USA, Netherlands, Belgium, France, Italy, 
Ireland, and Sweden.8,11,16,17 Demographic, ascertainment, 
and quality control details of these samples have been 
published previously.8,11,16,17 All participating individuals 
gave written informed consent, and patients were selected 
for sporadic ALS. Samples were matched for geographical 
origin and ethnic origin only.
This research was approved by the research ethics 
committees of each relevant institution for all cohorts.
Procedures
DNA was extracted by use of standard methods at three 
centres within 1 week of the blood being drawn  (usually 
on the same day) and was stored centrally at the UK DNA 
banking network in Manchester. We used a barcode-
based sample tracking system to minimise the risk of 
clerical error. 
Genotyping of DNA from samples held with the UK 
MND DNA bank was done with Illumina HumanHap550 
BeadChips (Illumina, CA, USA) by UCL Genomics, 
London, UK. All DNA samples went through stringent 
quality control, and processing was done under full 
laboratory information management system control. The 
raw data were analysed with GenomeStudio (Illumina) 
and extracted for statistical analysis. 
Quality control procedures were applied to individual 
and SNP data (webappendix pp 1–3). Individuals were 
excluded if more than 1% of their genotypic data was 
missing; if they had abnormal heterozygosity, poor 
cluster separation, or a sex assignment that conﬂ icted 
with phenotypic data; if they shared more than 5% of 
alleles identical by descent with any other study member; 
or if they were of non-European ancestry. SNPs with 
minor allele frequency less than 1%, showing non-
random missingness between genotypes or cases and 
controls, or showing departure from Hardy-Weinberg 
equilibrium (p<1×10–⁶) were excluded.
For the joint analysis, raw genotypes were obtained 
from public databases or directly from research groups 
and merged into a single ﬁ le for analysis, with a covariate 
ﬁ le listing the site of origin. Genotyping and quality 
control measures for the studies in the joint analysis have 
been published previously.8,11,16,17
All data were deposited at the ALS online genetics 
database18 and the European genome-phenome archive. 
Statistical analysis 
We did power analysis with the Genetic Power Calculator.19 
For the independent analysis there was 80% power to detect 
a typical previously reported association with an odds ratio 
(OR) of 1∙2 and minor allele frequency of 0∙25 at p=0∙05. 
We report power at p=0∙05 in the independent analysis 
because, although we have done a GWAS, we are interested 
in replicating association at ﬁ ve speciﬁ ed loci (FGGY, 
DPP6, ITPR2, UNC13A, and chromosome 9p21.2). For the 
joint analysis, we investigated the possibility of new 
associations within the genome and therefore we corrected 
for multiple testing. We used Bonferroni correction, which 
assumes the tests of association at each of the 227 475 SNPs 
are independent; the corrected threshold is therefore 
2∙20×10–⁷ (0∙05/227 475), and there was 83·5% power to 
detect a similar variant at the threshold of p=2∙20×10–⁷. Our 
aim was to use all of the available samples.
For the joint analysis, population stratiﬁ cation was 
controlled for by principal component analysis in 
EIGENSTRAT.20 We used the Tracy-Widom distribution 
to calculate the number of signiﬁ cant principal 
components needed as covariates in subsequent analyses, 
using the twstats program of the Eigensoft package.21 
We tested association of genotypes with ALS by logistic 
regression with 30 principal components as covariates in 
the program PLINK (version 1.07).22 We used the 
expectation-maximisation algorithm—as used in PLINK—
for haplotype estimation. Haplotypic association with ALS 
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was tested with a sliding window of varying sizes, including 
a window suﬃ  cient to include all SNPs in the haplotype 
block that contained the most strongly associated SNPs.
We imputed genotypes by use of Impute2,23 with data 
from the 1000 Genomes Project and the International 
HapMap as templates.24 Genotype imputation allows 
the prediction of genotypes at untyped SNPs by the 
correlation between SNP genotypes in diﬀ erent 
populations. Association analysis can then be done on 
the predicted genotypes. Association analysis was done 
with SNPTEST,25 which accounts for uncertainty in the 
imputed genotypes, using the ﬁ rst ten principal 
components as covariates (the maximum possible). The 
correction for population stratiﬁ cation in the imputed 
data will have been weakened by the use of fewer 
principal components; however, the use of Impute2 
increased our ability to deal with genotype uncertainty. 
We did this to identify variants for follow-up genotyping 
in a focused region, and thus the trade-oﬀ  was deemed 
worthwhile.
Population attributable risk was estimated as: 
where q is the risk allele frequency, p=1–q, and genotype 
relative risk is denoted by g, with the subscript showing 
heterozygote or homozygote status. Penetrance for each 
genotype was estimated as:
where K is the lifetime prevalence and f is the genotype 
frequency.
Role of the funding source
The sponsor of the study had no role in study design, 
data analysis, data interpretation, writing of the report, 
or the decision to submit the paper for publication. The 
Motor Neurone Disease Association is the sponsor of 
the UK National MND DNA bank, and therefore had a 
role in data collection. The corresponding author had 
full access to all of the data in the study and had ﬁ nal 
responsibility for the decision to submit the paper 
for publication.
Results 
For the independent analysis, genotypes were obtained 
from 663 individuals in the UK MND DNA bank, 
1589 control samples from the DeCC study and BACCS, 
and 2930 control samples from the 1958 birth cohort. 
After quality control measures, samples were available 
from 599 people with ALS and 4144 control individuals. 
Table 1 summarises clinical features of the ALS cohort in 
the independent analysis.
For the joint analysis, genotypes were obtained from 
4312 patients with ALS and 8425 control individuals. 
After quality control measures, samples were available 
from 4133 patients with ALS and 8130 control individuals, 
which were typed for 227 475 SNPs to generate 
2 789 513 662 genotypes. Table 2 and the webappendix p 4 
summarise demographic data.
In the independent analysis, SNPs rs3849942 
(p=2∙22×10–⁶; OR 1∙39, 95% CI 1∙21–1∙59) and rs2814707 
(p=3∙32×10–⁶; 1∙38, 1∙20–1∙58) on chromosome 9 
showed association with ALS (ﬁ gure 1, table 3, 
webappendix pp 5–6). rs903603, which had strong 
linkage disequilibrium with the associated SNPs 
(D’=0∙98), was the SNP most strongly associated with 
ALS in the independent set (p=8∙92×10–⁸; OR 0∙71, 
95% CI 0∙63–0∙81). No other loci achieved genome-
wide signiﬁ cance.
In the joint analysis, rs3849942 (p=4∙64×10–¹⁰; OR 
1∙22, 95% CI 1∙15–1∙30), rs2814707 (p=4∙72×10–¹⁰; 1∙22, 
1∙15–1∙30), and rs903603 (p=1∙37×10–⁷; 0∙86, 0∙82–0∙91) 
showed association with ALS (ﬁ gure 2, table 3, 
webappendix pp 7–8). SNPs at other loci that were 
associated with ALS in previous studies did not reach 
signiﬁ cance in the joint analysis, except the previously 
associated SNP in UNC13A (rs12608932; table 3). The 
genotype relative risk for rs3849942 was 1∙24 
(heterozygote) and 1∙49 (homozygote), with minor 
allele frequencies of 0∙27 in patients with ALS and 0∙24 
in controls. The population attributable risk of 
rs3849942 was 0∙10 and the penetrance of the risk allele 
was 0∙004 (heterozygote) and 0∙005 (homozygote).
A haplotypic association of rs3849942 and rs10122902 
(omnibus p=1∙51×10–¹¹) was identiﬁ ed in the joint 
analysis. Of the three haplotypes in the population (GA, 
AG, and GG), one had equal frequency in people with 
ALS and controls (GA: frequency cases 0∙21, 
controls 0∙20; p=0·123), one was associated with 
increased risk of ALS (AG: frequency cases 0∙27, controls 
0∙23, p=7∙76×10–¹⁰), and was one associated with reduced 
risk of ALS (GG: frequency cases 0∙52, controls 0∙57; 
p=4∙83×10–¹¹). Similar results were obtained for the 
independent study: rs3849942 and rs10122902 showed 
(p2+2pqgAB+q
2gBB)–1
p2+2pqgAB+q
2gBB
fcaseK
fcontrol
Case cohort (n=599)
Presentation*
Bulbar symptoms 165 (28%)
Limb weakness 375 (63%)
Respiratory 11 (2%)
Mixed† 42 (7%)
Age of onset‡ (years) 60·7 (61·7, 22·9–86·5)
Diagnostic delay§ (months) 21·5 (18·3, 2·0–80·1) 
Data are number (%) or mean (median, range). *Data missing for six patients. 
†Simultaneously reported weakness of limbs and bulbar musculature. ‡Data 
missing for three patients. §Time between symptom onset and diagnosis. Data 
missing for eight patients.
Table 1: Clinical features of patients with amyotrophic lateral sclerosis in 
the independent analysis
For the MND DNA bank see 
http://www.mndassociation.
org/dna_bank/
For the amyotrophic lateral 
sclerosis online genetics 
database see http://alsod.iop.
kcl.ac.uk
For the European 
genome-phenome archive see 
http://www.ebi.ac.uk/ega
For the 1000 Genomes 
Project see http://
www.1000genomes.org
See Online for webappendix
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haplotypic association (omnibus p=1∙01×10–⁷), and the 
same three haplotypes had similar control frequencies 
(GA: frequency cases 0∙21, controls 0∙19, p=0·074; 
AG: frequency cases 0∙30, controls 0∙24, p=3∙18×10–⁶; 
GG: frequency cases 0∙48, controls 0∙57, p=4∙24×10–⁸). 
Longer SNP haplotypes did not result in stronger 
association in either part of the study (data not shown). 
The sliding window showed that pairs of SNPs within a 
106∙5 kb block of linkage disequilibrium ﬂ anked by 
rs4879515 and rs702231 were nearly all associated with 
ALS at p<1×10–³, whereas outside this region there were 
no signiﬁ cant associations. 
Imputation in the joint analysis in the region of interest 
(ie, the 3·6 Mb region identiﬁ ed by linkage) gave results 
for 21 899 imputed SNPs that were derived from 519 typed 
SNPs. Five SNPs were more strongly associated with ALS 
than was rs3849942; the most strongly associated SNP was 
a rare variant, chr9:27573575 (minor allele frequency 
0∙054; p=6∙40×10–¹⁵). The most strongly associated variant 
with a minor allele frequency greater than 0∙1 was 
rs13295103 (p=1∙97×10–¹²; ﬁ gure 3).
Discussion
In our independent study we have conﬁ rmed association 
of a chromosome 9 locus with ALS. We did not replicate 
any of the other previously reported associations, 
suggesting that our study gave a false-negative result or 
that they were population speciﬁ c or false-positive results 
(panel, table 3).8–12 In our joint analysis, which is the 
largest GWAS of ALS to date, chromosome 9p21.2 and 
Cases Controls Total Men
Belgium8 286 307 593 313
France16 230 700 930 805
Netherlands8,10,12 977 988 1965 1152
Ireland11 210 200 410 219
Italy17 259 241 500 271
Sweden8 422 441 863 481
USA16 923 904 1827 1061
UK16 227 205 432 264
UK MND DNA bank 599 0 599 382
DeCC study and BACCS 0 1505 1505 567
1958 birth cohort 0 2639 2639 1357
Total 4133 8130 12 263 6872
The ﬁ nal three rows refer to samples used in the independent study. 
DeCC=Depression Case Control. BACCS=Bipolar Aﬀ ective Case Control Study. 
Table 2: Characteristics of the component populations for the joint 
analysis after quality control
Figure 1: p values for association in the independent genome-wide association study
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Figure 2: p values for association in the joint analysis
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10
n for associated 
SNP in previous 
studies*
Associated 
SNP
Controls p value in 
previous 
studies
Independent analysis† Joint analysis‡
p value Minor allele frequency p value Minor allele frequency
Cases Controls Cases Controls
FGGY9 1287 rs6700125 1567 6·0×10⁴ 0·71 0·342 0·337 0·08 0·351 0·339
DPP612 1767 rs10260404 1916 5·4×10⁸ 0·89 0·397 0·395 0·08 0·391 0·380
ITPR210 1337 rs2306677 1356 3·28×10⁶ 0·98 0·100 0·100 0·97 0·100 0·096
UNC13A8 4855 rs12608932 14 953 2·53×10¹⁴ 0·42 0·366 0·354 5·14×10⁸ 0·382 0·344
9p21.28 4855 rs2814707 14 953 7·45×10⁹ 3·32×10⁶ 0·305 0·243 4·72×10¹⁰ 0·272 0·236
9p21.28 4855 rs3849942 14 953 1·01×10⁸ 2·22×10⁶ 0·304 0·241 4·64×10¹⁰ 0·271 0·235
9p21.28 4855 rs903603 14 953 ·· 8·92×10⁸ 0·411 0·493 1·37×10⁷ 0·456 0·492
Previously reported signiﬁ cant associations and the results we obtained for those genes in the two parts of this study are shown.8–10,12 *Total combined sample for the 
reported SNP, which includes a GWAS component and a non-GWAS follow-up study. †599 cases and 4144 controls. ‡4133 cases and 8130 controls.
Table 3: Associations for genes reported to be associated with amyotrophic lateral sclerosis in previous genome-wide association studies 
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UNC13A were the only signiﬁ cantly associated loci. The 
association of UNC13A with ALS was weaker in the joint 
analysis than in the study that identiﬁ ed the association,8 
which was well powered and replicated the results within 
the same study. Our independent samples do not show 
the association, possibly because the UNC13A variation 
is not a major cause of ALS in the UK, and so adding in 
these samples to the joint analysis we inevitably weaken 
the previously reported association. Given that the 
heritability of sporadic ALS is 0∙61 (95% CI 0∙38–0∙78),26 
our ﬁ ndings suggest that even larger GWAS are required 
to have suﬃ  cient power to detect genetic variations 
responsible for ALS. A potential limitation of this study 
is that not all control individuals were age and sex 
matched, although they were matched for geographical 
origin and ancestry. For a disease as rare as ALS, age and 
sex matching does not increase statistical power, whereas 
it would for a more common disorder. 
The associated 9p21 locus is the focus of much interest 
for researchers of both ALS and frontotemporal 
dementia. Although frontotemporal dementia and ALS 
are independent diseases, there is some overlap. About 
5% of people with ALS have overt frontotemporal 
dementia and up to 51% have subtle cognitive deﬁ cits 
that suggest frontal and temporal lobe dysfunction.27 
Conversely, about 50% of people with frontotemporal 
dementia have features of motor neuron degeneration.28 
A locus on chromosome 9 has been independently 
linked to ALS–frontotemporal dementia in seven 
families;2–7 this 3∙6 Mb locus is deﬁ ned across studies by 
the ﬂ anking markers D9S169 and D9S251. The SNPs we 
have identiﬁ ed lie within this region, with the peak 
association at 106∙5 Kb. A GWAS that used pathological 
subtyping of patients with frontotemporal dementia to 
increase homogeneity also identiﬁ ed the same SNPs as 
those most strongly associated with sporadic 
Figure 3: Genetic architecture of the associated region
Circles=–log10 of the p value of association with amyotrophic lateral sclerosis for typed and imputed single nucleotide polymorphisms in the joint analysis, coloured 
according to linkage disequilibrium with rs3849942 (shown as a purple diamond) as measured by r2. Blue lines=recombination rate across the locus based on the 
1000 genomes project. Genes in the region are displayed below the graph. Arrows indicate the direction of transcription.
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frontotemporal dementia (rs3849942 p=1∙38×10–⁶ and 
rs2814707 p=5∙72×10–⁶).29 Therefore, variation in the 
same gene is likely to be responsible for sporadic ALS, 
sporadic frontotemporal dementia, and familial ALS–
frontotemporal dementia. Assuming that the association 
locus is the same as the linkage locus, the region of 
interest in families with ALS–fronto temporal dementia 
must now be thought to be much narrower than that 
deﬁ ned by recombination; however, if a synthetic 
association of rare variants and ALS is being detected, 
the disease-causing variation could still lie a substantial 
distance from the association peak.30 
Penetrance is about 20% in the family with the 
strongest association between chromosome 9 and ALS–
frontotemporal dementia.3 Thus, familial variants might 
underlie at least some of the sporadic cases of ALS and 
frontotemporal dementia. The large signal seen in our 
independent study of UK samples is consistent with a 
founder eﬀ ect in the UK population, which possibly 
extends out to other populations. In this respect, that a 
GWAS of a cohort of Finnish patients with ALS and 
controls also detected the chromosome 9p locus 
(rs3849942 p=9∙11×10–¹¹) is interesting.31 This association 
signal was driven mainly by people with familial ALS; 
the most strongly associated SNP in this subset of 
patients was rs2225389 (p=2∙23×10–¹²). All the patients 
with familial ALS who were not homozygous for the 
D90A allele of the SOD1 gene, and almost 20% of the 
patients with sporadic ALS, shared a 42-SNP haplotype, 
which strongly suggests a founder eﬀ ect for the 
chromosome 9p locus, at least in Finland. However, the 
penetrance of the associated risk allele of rs3849942 in 
sporadic ALS in our study is only slightly higher than 
the background risk of ALS (0∙36–0∙45%),1 whereas the 
penetrance of the familial variants is about 20%; thus, 
the likelihood that the same variation is responsible for 
both familial and sporadic ALS is questionable, which 
makes a founder eﬀ ect less likely. The signiﬁ cant 
association of rs3849942 with sporadic ALS in our joint 
analysis including multiple populations suggests that a 
common genetic variation might be contributing to 
disease risk. The two-SNP haplotype that was most 
strongly associated with ALS in the joint analysis 
(rs3849942-rs10122902) mimics the behaviour of the 
APOE association with Alzheimer’s disease; the three 
APOE alleles—ε2, ε3, and ε4—are in fact pairs of alleles 
at two SNPs forming a  haplotype. When a haplotype is 
formed from alleles at two SNPs there are four possible 
haplotypes, although not all will necessarily exist in the 
population. For both the rs3849942-rs10122902 haplotype 
in ALS and the APOE haplotype in Alzheimer’s disease, 
only three of the four possible haplotypes are present, 
and the fourth does not exist in the population. In both 
cases, all identiﬁ ed haplotypes are common, and one is 
associated with risk of the disease (APOE ε4 in 
Alzheimer’s disease; AG in ALS), one is associated with 
protection from the disease (APOE ε2 in Alzheimer’s 
disease; GG in ALS), and one is neutral (APOE ε3 in 
Alzheimer’s disease; GA in ALS). Thus, common 
variation, as with APOE in Alzheimer’s disease, rather 
than a founder eﬀ ect, could be responsible for sporadic 
ALS. However, because the penetrance at a functional 
variant might be much higher than at an associated tag 
SNP, which would account for the discrepancy between 
the penetrance for familial ALS and sporadic ALS, a 
founder eﬀ ect cannot be excluded. There must be 
multiple variants worldwide because families with 
chromosome 9p-linked ALS–frontotemporal dementia 
do not all share a common haplotype, and so multiple 
founders must exist. However, the chromosome 9p locus 
is important in ALS because the population attributable 
risk estimate shows that it is involved in 10% of all cases 
of sporadic ALS.
The disease-associated SNPs we have identiﬁ ed lie 
between two genes, C9orf72 and MOBKL2B, and are 
close to IFNK, which lies in an intron of MOBKL2B. 
The protein encoded by MOBKL2B is Mps one binder 
kinase activator-like 2B, which is involved in kinase 
regulation. On the opposite strand at the same location 
is IFNK, which encodes interferon κ precursor, which is 
important for immunity to viral infection. The SNPs 
comprising the most strongly associated haplotype 
(rs3849942 and rs10122902) and imputed SNP 
(chr9:27573575) overlap or lie within C9orf72, which 
encodes a protein that might be involved in cell 
development and possibly spermatogenesis.32
Panel: Research in context
Systematic review
To identify previously published genome-wide association studies (GWAS) in amyotrophic 
lateral sclerosis (ALS), we searched PubMed and the ALSOD database (http://alsod.iop.kcl.
ac.uk), and contacted known ALS genetics research groups. Four GWAS reported ﬁ ndings 
that reached genome-wide signiﬁ cance;8–12 we designed the independent study to replicate 
these. Association studies were selected for the joint analysis if research diagnostic criteria 
for ALS were used, if microarrays of at least 300 000 single nucleotide polymorphisms were 
used, and if individual rather than pooled genotypes were available. Because the main 
ﬁ nding of the independent and joint analyses was of an association to a region on 
chromosome 9 also known to be associated with familial ALS–frontotemporal dementia 
and sporadic frontotemporal dementia, we searched PubMed and contacted research 
groups and identiﬁ ed a further seven families with ALS–frontotemporal dementia2–4,7 and a 
GWAS of frontotemporal dementia.29 These linkage data have been well summarised in a 
linkage paper.4
Interpretation
The ALS-associated locus on chromosome 9p was independently replicated, and no other loci 
were identiﬁ ed, suggesting that even larger genome-wide association studies are needed. We 
have shown the association signal on chromosome 9p lies in a well circumscribed block of 
linkage disequilibrium of about 106·5 Kb in size, which is ﬂ anked by markers rs4879515 and 
rs702231 and includes three annotated genes. This locus has also previously been implicated 
in sporadic frontotemporal dementia and in families with ALS–frontotemporal dementia. 
Because there is pathological and clinical overlap of ALS and frontotemporal dementia, the 
most logical interpretation is that dysfunction of a single gene product is responsible for 
some cases of ALS, frontotemporal dementia, and ALS–frontotemporal dementia. 
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Although linkage of ALS–frontotemporal dementia to 
this region of chromosome 9 was ﬁ rst identiﬁ ed in 
2006,2,3 sequencing has not yet yielded a disease-causing 
variant such as a non-synonymous SNP or splice-site 
variation. If this remains the case, one explanation could 
be that the variation is tagged by SNPs but not easily 
detected by exome capture and high throughput 
sequencing or Sanger sequencing. The disease-causing 
variant might be in an unknown exon or gene and has 
therefore not been sequenced, or it might be a 
trinucleotide repeat expansion in an intron, although 
such repeats are not seen in the surrounding region. 
Copy number variation is not necessarily easily detected, 
depending on the sequencing method used, but three 
microarray-based studies in ALS have not detected ALS-
associated copy number variation in this region of 
chromosome 9.33–35 Finally, a microRNA or non-annotated 
gene that has not been examined, or an inversion, which 
would be diﬃ  cult to detect by sequencing, might be the 
disease-causing variant. Our results suggest genetic 
variation at this locus on chromosome 9 causes sporadic 
amyothophic lateral sclerosis and familial ALS–
frontotemporal dementia. Resequencing studies and 
then functional analyses are needed to identify the 
defective gene.
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